Grants and Contributions:
Title:
Boosting Innovation Capacity of PGX Technology Towards Pharmaceutical Applications
Agreement Number:
980717
Agreement Value:
$480,000.00
Agreement Date:
Nov 1, 2021 - Mar 31, 2023
Description:
Ceapro will further develop the Pressurized Gas eXpanded (PGX) platform technology by designing a pharmaceutical PGX processing unit and bioactive impregnation and loading units. These new units will be used to generate active pharmaceutical ingredients for trials required to confirm immune-boosting benefits and address conditions such as pain, depression, sleep disorders, anxiety, and lung fibrosis.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6E 6W2
Reference Number:
172-2021-2022-Q3-980717
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
887207280
Recipient Type:
For-profit organization
Recipient's Legal Name:
CEAPRO Inc.
Federal Riding Name:
Edmonton Strathcona
Federal Riding Number:
48019
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410